QLT Loses Again To Takeda Abbott In Cancer Drug Clash

Law360, New York (January 23, 2006, 12:00 AM EST) -- In the battle over a prostate cancer treatment, an Illinois federal court handed Takeda Abbott Pharmaceuticals Inc. another key victory this week after rejecting the patent “unenforceability” defense asserted by pharmaceutical companies QLT USA Inc. and Sanofi-Synthelabo Inc.

On Monday, the U.S. District Court for the Northern District of Illinois released its decision, denying the argument put forth by co-defendants QLT USA Inc. and Sanofi-Synthelabo Inc., a unit of French pharmaceutical giant Sanofi-Aventis, and siding with plaintiff TAP.

The defendants claimed in court papers that TAP’s...
To view the full article, register now.